Agency Information Collection Activities: Proposed Collection; Comment Request, 17614-17615 [2021-06887]

Download as PDF 17614 Federal Register / Vol. 86, No. 63 / Monday, April 5, 2021 / Notices jbell on DSKJLSW7X2PROD with NOTICES (3) Two oral public comment sessions: One session will be open to any newborn screening related topic. The other public comment period will specifically address the Committee’s review of the evidence review process (e.g., nomination form, consumerfriendly guidance materials, review of conditions on the RUSP). Please note, if you wish to register to submit oral public comments on the review of the Committee’s evidence review process we request that you also submit a written version of your remarks; (4) Committee discussion of Continuity of Operations Planning and COVID–19; and, (5) Newborn screening data sources. The agenda for this meeting does not include any plans for recommending a condition for inclusion in the RUSP. However, as noted in the agenda items, the Committee may hold a vote on whether or not to recommend a nominated condition (MPS II) to full evidence review, which may lead to such a recommendation at a future time. Agenda items are subject to change as priorities dictate. Information about the ACHDNC, including a roster of members and past meeting summaries, is also available on the ACHDNC website previously listed. As noted above, members of the public will have the opportunity to provide comments. Public participants providing general oral comments may submit written statements in advance of the scheduled meeting. We specifically request that public participants providing oral comment on the review of the Committee’s evidence review process also submit a written version of their remarks. Oral comments will be honored in the order they are requested and may be limited as time allows. Requests to provide a written statement or make oral comments to the ACHDNC must be submitted via the registration website by 10:00 a.m. ET on Monday, May 10, 2021. Individuals who need special assistance or another reasonable accommodation should notify Alaina Harris at the address and phone number listed above at least 10 business days prior to the meeting. Maria G. Button, Director, Executive Secretariat. [FR Doc. 2021–06940 Filed 4–2–21; 8:45 am] BILLING CODE 4165–15–P VerDate Sep<11>2014 17:23 Apr 02, 2021 Jkt 253001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal NCI committees that will decide whether NCI should support requests and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel; FEB2021 Cycle 37 NExT SEP Committee Meeting. Date: April 21, 2021. Time: 9:00 a.m. to 3:00 p.m. Agenda: To evaluate the NCI Experimental Therapeutics Program Portfolio. Place: National Institutes of Health, 9000 Rockville Pike, Building 31, Room 3A44, Bethesda, Maryland 20892 (WebEx Meeting). Contact Persons: Barbara Mroczkowski, Ph.D. Executive Secretary, Discovery Experimental Therapeutics Program, National Cancer Institute, NIH, 31 Center Drive, Room 3A44, Bethesda, MD 20817, (301) 496–4291, mroczkoskib@mail.nih.gov. Toby Hecht, Ph.D., Executive Secretary, Development Experimental Therapeutics Program, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 3W110, Rockville, MD 20850, (240) 276–5683, toby.hecht2@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) PO 00000 Frm 00029 Fmt 4703 Sfmt 4703 Dated: March 30, 2021. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2021–06890 Filed 4–2–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Agency Information Collection Activities: Proposed Collection; Comment Request In compliance with section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 concerning opportunity for public comment on proposed collections of information, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the information collection plans, call the SAMHSA Reports Clearance Officer on (240) 276– 0361. Comments are invited on: (a) Whether the proposed collections of information are necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Proposed Project: 2022 National Survey on Drug Use and Health (OMB No. 0930–0110) The National Survey on Drug Use and Health (NSDUH) is a survey of the U.S. civilian, non-institutionalized population aged 12 years old or older. The data are used to determine the prevalence of use of tobacco products, alcohol, illicit substances, and illicit use of prescription drugs. The results are used by SAMHSA, the Office of National Drug Control Policy (ONDCP), federal government agencies, and other organizations and researchers to establish policy, direct program activities, and better allocate resources. As certain parts of the United States reduce COVID–19 restrictions, NSDUH in-person data collection will proceed where possible. However, to ensure E:\FR\FM\05APN1.SGM 05APN1 17615 Federal Register / Vol. 86, No. 63 / Monday, April 5, 2021 / Notices sufficient data are collected to produce nationally representative estimates for the 2022 survey, NSDUH will continue to employ a mix of in-person and webbased modes of administration to allow those respondents living in areas with COVID–19 restrictions the opportunity to participate. If the COVID–19 pandemic subsides to such levels to allow in-person data collection to resume nationwide, SAMHSA may reassess that multimode data collection model as part of the 2022 NSDUH. In those areas where in-person data collection is permitted, NSDUH protocols, processes, and materials will continue to reflect the need to ensure the safety of respondents and field interviewers with respect to COVID– 19—after initial implementation of such measures beginning in October 2020— which include equipping field interviewers with masks, gloves, disinfecting wipes, and hand sanitizer for use during data collection and providing a COVID–19 risk information form to all respondents. In addition, the NSDUH questionnaire must be updated periodically to reflect changing substance use and mental health issues and to continue producing current data. For the 2022 NSDUH, the following questionnaire updates are planned: (1) Replacing the tobacco module with a redesigned nicotine module that includes questions about vaping, removes low priority items to reduce respondent burden and eliminates outdated terminology; (2) revising the marijuana module to include questions about the use of CBD, update questions on the mode of administration and eliminate outdated terminology and includes changes to the market information for marijuana questions; (3) redesigning the adult and youth mental health services utilization modules into one Mental Health Service Utilization model to remove questions with outdated terminology and include questions about newer treatments with recent increases in popularity; and (4) replacing the drug treatment module with a redesigned alcohol and drug treatment module that includes questions about newer treatments and those that have increased in popularity, as well as eliminating outdated terminology and reducing respondent burden. As with all NSDUH/NHSDA 1 surveys conducted since 1999, the sample size of the NSDUH main study for 2022 will be sufficient to permit prevalence estimates for each of the fifty states and the District of Columbia. The total annual burden estimate for the NSDUH main study is shown below in Table 1. TABLE 1—ANNUALIZED ESTIMATED BURDEN FOR 2022 NSDUH Number of respondents Instrument Total number of responses Hours per response Total burden hours Household Screening ........................................................... Interview ............................................................................... Screening Verification .......................................................... Interview Verification ............................................................ 168,674 67,507 5,060 10,126 1 1 1 1 168,674 67,507 5,060 10,126 0.083 1.000 0.067 0.067 14,000 67,507 339 678 Total .............................................................................. 168,674 ........................ 251,367 ........................ 82,524 Send comments to Carlos Graham, SAMHSA Reports Clearance Officer, 5600 Fisher Lane, Room 15E57A, Rockville, MD 20852 OR email him a copy at carlos.graham@samhsa.hhs.gov. Written comments should be received by June 4, 2021. Carlos Graham, Social Science Analyst. [FR Doc. 2021–06887 Filed 4–2–21; 8:45 am] BILLING CODE 4162–20–P DEPARTMENT OF HOMELAND SECURITY The Coast Guard published a document in the Federal Register on March 30, 2021, concerning a notice of a decision on a consolidation of Coast Guard boat stations. The document contained an incorrect docket number. DATES: This correction is effective April 5, 2021. FOR FURTHER INFORMATION CONTACT: For information about this document call or email Todd Aikins, Coast Guard Office of Boat Forces; telephone 202–372– 2463, email todd.r.aikins@uscg.mil. SUPPLEMENTARY INFORMATION: SUMMARY: Correction In the Federal Register of March 30, 2021, in FR Doc. 2021–06461, on page 16604, in the second column, in the heading, the docket number, ‘‘USCG– 2021–0178’’, is corrected to read ‘‘USCG–2020–0042’’. This corrects the error in the docket number and will ensure that this decision notice will be placed in the same docket as the notice soliciting comments regarding these boat stations (85 FR 8601, February 14, 2020). Coast Guard [Docket No. USCG–2020–0042] Consolidation of Redundant Coast Guard Boat Stations—Decision; Correction jbell on DSKJLSW7X2PROD with NOTICES Responses per respondent Coast Guard, DHS. Notice; correction to docket number. AGENCY: ACTION: Dated: March 30, 2021. J.E. McLeod, Acting Office Chief, Office of Regulations and Administrative Law. [FR Doc. 2021–06876 Filed 4–2–21; 8:45 am] BILLING CODE 9110–04–P DEPARTMENT OF HOMELAND SECURITY Federal Emergency Management Agency [Docket ID: FEMA–2020–0039; OMB No. 1660–0006] Agency Information Collection Activities: Submission for OMB Review; Comment Request; National Flood Insurance Program Policy Forms Federal Emergency Management Agency, Department of Homeland Security. ACTION: 30 Day Notice of Reinstatement and request for comments. AGENCY: The Federal Emergency Management Agency (FEMA), as part of SUMMARY: 1 Prior to 2002, the NSDUH was referred to as the National Household Survey on Drug Abuse (NHSDA). VerDate Sep<11>2014 17:23 Apr 02, 2021 Jkt 253001 PO 00000 Frm 00030 Fmt 4703 Sfmt 4703 E:\FR\FM\05APN1.SGM 05APN1

Agencies

[Federal Register Volume 86, Number 63 (Monday, April 5, 2021)]
[Notices]
[Pages 17614-17615]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-06887]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Agency Information Collection Activities: Proposed Collection; 
Comment Request

    In compliance with section 3506(c)(2)(A) of the Paperwork Reduction 
Act of 1995 concerning opportunity for public comment on proposed 
collections of information, the Substance Abuse and Mental Health 
Services Administration (SAMHSA) will publish periodic summaries of 
proposed projects. To request more information on the proposed projects 
or to obtain a copy of the information collection plans, call the 
SAMHSA Reports Clearance Officer on (240) 276-0361.
    Comments are invited on: (a) Whether the proposed collections of 
information are necessary for the proper performance of the functions 
of the agency, including whether the information shall have practical 
utility; (b) the accuracy of the agency's estimate of the burden of the 
proposed collection of information; (c) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (d) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques or other 
forms of information technology.

Proposed Project: 2022 National Survey on Drug Use and Health (OMB No. 
0930-0110)

    The National Survey on Drug Use and Health (NSDUH) is a survey of 
the U.S. civilian, non-institutionalized population aged 12 years old 
or older. The data are used to determine the prevalence of use of 
tobacco products, alcohol, illicit substances, and illicit use of 
prescription drugs. The results are used by SAMHSA, the Office of 
National Drug Control Policy (ONDCP), federal government agencies, and 
other organizations and researchers to establish policy, direct program 
activities, and better allocate resources.
    As certain parts of the United States reduce COVID-19 restrictions, 
NSDUH in-person data collection will proceed where possible. However, 
to ensure

[[Page 17615]]

sufficient data are collected to produce nationally representative 
estimates for the 2022 survey, NSDUH will continue to employ a mix of 
in-person and web-based modes of administration to allow those 
respondents living in areas with COVID-19 restrictions the opportunity 
to participate. If the COVID-19 pandemic subsides to such levels to 
allow in-person data collection to resume nationwide, SAMHSA may 
reassess that multimode data collection model as part of the 2022 
NSDUH.
    In those areas where in-person data collection is permitted, NSDUH 
protocols, processes, and materials will continue to reflect the need 
to ensure the safety of respondents and field interviewers with respect 
to COVID-19--after initial implementation of such measures beginning in 
October 2020--which include equipping field interviewers with masks, 
gloves, disinfecting wipes, and hand sanitizer for use during data 
collection and providing a COVID-19 risk information form to all 
respondents.
    In addition, the NSDUH questionnaire must be updated periodically 
to reflect changing substance use and mental health issues and to 
continue producing current data. For the 2022 NSDUH, the following 
questionnaire updates are planned: (1) Replacing the tobacco module 
with a redesigned nicotine module that includes questions about vaping, 
removes low priority items to reduce respondent burden and eliminates 
outdated terminology; (2) revising the marijuana module to include 
questions about the use of CBD, update questions on the mode of 
administration and eliminate outdated terminology and includes changes 
to the market information for marijuana questions; (3) redesigning the 
adult and youth mental health services utilization modules into one 
Mental Health Service Utilization model to remove questions with 
outdated terminology and include questions about newer treatments with 
recent increases in popularity; and (4) replacing the drug treatment 
module with a redesigned alcohol and drug treatment module that 
includes questions about newer treatments and those that have increased 
in popularity, as well as eliminating outdated terminology and reducing 
respondent burden.
    As with all NSDUH/NHSDA \1\ surveys conducted since 1999, the 
sample size of the NSDUH main study for 2022 will be sufficient to 
permit prevalence estimates for each of the fifty states and the 
District of Columbia. The total annual burden estimate for the NSDUH 
main study is shown below in Table 1.
---------------------------------------------------------------------------

    \1\ Prior to 2002, the NSDUH was referred to as the National 
Household Survey on Drug Abuse (NHSDA).

                               Table 1--Annualized Estimated Burden for 2022 NSDUH
----------------------------------------------------------------------------------------------------------------
                                     Number of     Responses per   Total number      Hours per     Total burden
           Instrument               respondents     respondent     of responses      response          hours
----------------------------------------------------------------------------------------------------------------
Household Screening.............         168,674               1         168,674           0.083          14,000
Interview.......................          67,507               1          67,507           1.000          67,507
Screening Verification..........           5,060               1           5,060           0.067             339
Interview Verification..........          10,126               1          10,126           0.067             678
                                 -------------------------------------------------------------------------------
    Total.......................         168,674  ..............         251,367  ..............          82,524
----------------------------------------------------------------------------------------------------------------

    Send comments to Carlos Graham, SAMHSA Reports Clearance Officer, 
5600 Fisher Lane, Room 15E57A, Rockville, MD 20852 OR email him a copy 
at [email protected]. Written comments should be received by 
June 4, 2021.

Carlos Graham,
Social Science Analyst.
[FR Doc. 2021-06887 Filed 4-2-21; 8:45 am]
BILLING CODE 4162-20-P